Midline glioma is a tumor type that can be found in many locations including the brainstem and the thalamus, with these cases being collectively classified as diffuse midline glioma. However, despite their grouping there are significant differences in the transcriptome, or genes expressed within in a tumor, based on location. Thalamic glioma makes up 1% of all brain tumors and almost 15% of all malignant pediatric tumors of the brain. There has been a recent research focus on the diffuse midline gliomas of the pons, also known as diffuse intrinsic pontine glioma (DIPG). However, still little is known about diffuse midline gliomas of the thalamus. This gap in knowledge is partially a consequence of there being no available in vivo models related to thalamic glioma. Researchers aim to develop an orthotopic xenograft model of thalamic glioma, models created by the implantation of tumor cells into a model animal, in this case mice. Researchers will attempt varying amounts of cells, coordinates, and ages of mice in order to accomplish this. Mice will then be monitored and observed to better understand thalamic glioma. Researchers will accomplish this through utilization of CBTN cell lines from thalamic glioma patient(s). This study will hopefully lay groundwork for future studies of thalamic glioma and highlight differences in development and response to therapy as compared to diffuse midline glioma.
What are the goals of this project?
Researchers will implant CBTN provided cell lines for thalamic glioma into mice to create in vivo models for future studies.
What is the impact of this project?
Progress in the treatment of thalamic gliomas suffers from a gap in research and this project hopes to fill that gap, thus increasing the likelihood that new therapies are developed to tackle this tumor type.
Why is the CBTN request important to this project?
High quality cell lines are needed to complete this work and such cell lines are made available to researchers through CBTN.